BMJ2d
AB1241 DESIGN OF AVACOSTAR: A REAL-WORLD STUDY OF AVACOPAN IN ANCA-ASSOCIATED VASCULITIS (AAV)
Background: Avacopan, a first-in-class oral C5aR antagonist, was shown to be superior to a prednisone taper in sustaining remission, and was associated with improved estimated glomerular filtration ...
BMJ2d
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
Objective To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). Methods This phase III, randomised, double-blind, placebo-controlled study enrolled ...
BMJ2d
Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation
Correspondence to Dr Naotomo Kambe, Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto 606-8507, Japan; nkambe{at}kuhp.kyoto-u.ac.jp Results The study population ...
BMJ3d
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis
Objectives The prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases who are frequently treated with disease modifying therapies remains poorly understood. This ...
BMJ4d
THU0178 Long term safety profile of methotrexate in patients with ra in routine care
Background Methotrexate is the anchor drug used most widely as monotherapy or combination therapy with other DMARDS & biologics in treatment of RA. It is widely perceived by clinicians to have ...
BMJ5d
Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells
Objectives Syntenin-1, a novel endogenous ligand, was discovered to be enriched in rheumatoid arthritis (RA) specimens compared with osteoarthritis synovial fluid and normal synovial tissue (ST).
BMJ6d
POS1470 POOR LONG-TERM OUTCOMES AND SUBSTANTIAL UNMET NEEDS IN EUROPEAN PATIENTS WITH LUPUS NEPHRITIS
1 University Hospitals of Strasbourg, French National Reference Center for Rare Auto-immune Diseases (RESO), Department of Rheumatology, Strasbourg, France 2 Maple Health Group, LLC, New York, United ...
BMJ7d
AB1192 PREVALENCE, RISK FACTORS, AND OUTCOMES OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN CHINESE: A MULTI-CENTRED COHORT STUDY
1 Alice Ho Miu Ling Nethersole Hospital, Department of Medicine, Tai Po, Hong Kong (SAR) 2 The Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Medicine and Therapeutics, ...
BMJ8d
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical ...
BMJ8d
Single-cell RNA-seq analysis identifies meniscus progenitors and reveals the progression of meniscus degeneration
Correspondence to Dr Zhiqi Zhang, Department of Joint Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, China; zhzhiqi{at}mail.sysu.edu.cn; Dr Weiming Liao; ...
BMJ8d
When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
Objective: To evaluate the efficacy and safety of adding sulfasalazine to leflunomide treatment compared with switching to sulfasalazine alone in patients with RA with an inadequate response to ...
BMJ8d
Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...